Active Biotech - the first day for trading in the new single class of shares will be December 19


According to the decision from the Extraordinary General Meeting, the change shall be effected in the VPC (Swedish Securities Register Center) system on December 23, 2003 when all A and B shares are converted into one single class of shares.
The change means that:
Today, December 18 is the last day for trading in Series A and Series B Active Biotech AB shares on The Stockholm Stock Exchange (Stockholmsbörsen).
Tomorrow, December 19 is the first day for trading in the new single class of shares.
VPC will automatically effect the change in class of shares by December 23 and distribute notifications to former owners of A shares with information regarding the change included.
Lund, December 18, 2003
Active Biotech AB (publ)
Sven Andréasson
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/ inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund
Tel +46 46 19 20 00
Fax +46 46 19 20 50